A Multicenter, Randomized, Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Brivanib Alaninate (ZL-2301) Combined With Best Supportive Care (BSC) and Pharmacokinetic Profiles of Brivanib Alaninate in Patients With Advanced Hepatocellular Carcinoma (HCC) Failed or Intolerant of Standard Systemic Chemotherapy and/or Sorafenib
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors ZAI Lab
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.
- 02 Jul 2019 Status changed from recruiting to active, no longer recruiting.